CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oncoinvent ASA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oncoinvent ASA
Gullhaugveien 7
Phone: +47 22183305p:+47 22183305 Oslo, 0484  Norway Ticker: ONCINONCIN

Business Summary
Oncoinvent ASA is a Norway-based privately held radiopharmaceutical company. The Company is engaged in the development of alpha-emitting radiotherapeutics that provide better treatment options to cancer patients. The Company offers Radspherin, which is alpha-emitting radioactive microsphere therapy designed for the treatment of metastatic cancers in body cavities. The product candidate is a suspension of inorganic microspheres labelled with an alpha-emitting radioisotope for local administration. More specifically it consists of with calcium carbonate micro particles labelled with the radioisotope Radium-224d. The therapeutic goal is to treat residual micro metastases remaining after surgery in intracavitary surfaces and liquid without subjecting deeper regions of organs and tissues to harmful radiation doses.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202412/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Roy H.Larsen
Chief Executive Officer AndersMansson
Chief Financial Officer ToreKvam
Chief Scientific Officer Tina B.Bonsdorff 52
Chief Medical Officer KariMyren

General Information
Number of Employees: 46 (As of 12/31/2023)
Outstanding Shares: 92,243,343 (As of 9/30/2024)
Stock Exchange: OSL
Email Address: oncoinvent@oncoinvent.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, January 30, 2025